AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
AstraZeneca (NASDAQ:AZN) said on Friday that its gastric cancer treatment, IMFINZI, demonstrated a statistically significant ...
A treatment combining AstraZeneca’s (LSE: AZN) immunotherapy Imfinzi (durvalumab) with chemotherapy has significantly reduced ...
The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...
Pharmaceutical Technology on MSN5d
EU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLCAstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination ...
AstraZeneca said its Imfinzi drug when used with chemotherapy had shown “statistically significant and clinically meaningful improvement” in survival in resectable early-stage gastric and ...
and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi ® (durvalumab) in the treatment of late-stage pancreatic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback